10-Q: AptarGroup Q3 Earnings Surge on Strategic Acquisitions

AptarGroup, Inc. reported a significant increase in net income and EPS for Q3 2025, driven by a one-time gain from an equity investment remeasurement and a lower effective tax rate, alongside modest core sales growth.

Summary

• Net sales for the third quarter of 2025 increased by 6% to $961.1 million, compared to $909.3 million in Q3 2024.
• For the nine months ended September 30, 2025, net sales rose 3% to $2.81 billion, up from $2.73 billion in the prior year.
• Core sales, excluding currency effects and acquisitions, increased by 1% for both the third quarter and the first nine months of 2025.
• Net income attributable to AptarGroup, Inc. surged 27.9% to $127.9 million in Q3 2025, and 16.4% to $318.4 million for the first nine months.
• Diluted EPS increased to $1.92 in Q3 2025 from $1.48 in Q3 2024, and to $4.75 for the nine months from $4.05 in the prior year.
• The effective tax rate decreased to 17.1% in Q3 2025 (from 23.8% in Q3 2024) and to 20.4% for the nine months (from 22.7% in 2024), primarily due to a gain from equity investment remeasurement and deferred tax benefits.
• Aptar Pharma segment's core sales grew 2% in Q3 and 2% for the nine months, driven by strong demand in prescription drug, injectables, and active material science solutions.
• Aptar Beauty segment's core sales remained flat in both periods, with strong personal care sales offsetting declines in beauty and home care.
• Aptar Closures segment's core sales decreased 1% in Q3 but increased 1% for the nine months, with beverage sales growth partially offset by lower tooling sales and resin cost pass-throughs.
• The company completed the acquisition of an additional 31% equity interest in BTY, increasing beneficial ownership to 80%, which resulted in a $26.5 million pre-tax gain from remeasurement of the previously held minority interest.
• A share repurchase authorization of up to $500 million was announced on October 10, 2024, with $272.7 million remaining as of September 30, 2025.
• Restructuring costs decreased to $2.2 million in Q3 2025 and $5.8 million for the nine months, down from $3.9 million and $9.7 million respectively in the prior year periods.

Sentiment

Score: 7

Explanation: The company reported strong net income and EPS growth, primarily driven by a significant one-time gain from an equity investment remeasurement and a lower effective tax rate. While core sales growth was modest and operating income slightly declined in the quarter due to increased costs, the Pharma segment's performance was robust, and strategic acquisitions position the company for future growth. The balance sheet remains strong with healthy leverage and interest coverage ratios. The outlook for Q4 EPS is positive, suggesting continued confidence despite some segment-specific softness.

Positives

• Net income attributable to AptarGroup, Inc. increased significantly by 27.9% in Q3 2025 and 16.4% for the nine months, reaching $127.9 million and $318.4 million respectively.
• Diluted earnings per share (EPS) saw strong growth, rising to $1.92 in Q3 2025 (from $1.48) and $4.75 for the nine months (from $4.05).
• The effective tax rate decreased due to a $26.5 million gain from the remeasurement of an equity investment (BTY) and deferred tax benefits, positively impacting net income.
• Aptar Pharma segment demonstrated robust performance with 2% core sales growth in both Q3 and YTD, driven by strong demand in prescription drug (+3% Q3, +7% YTD) and injectables (+18% Q3, +6% YTD).
• Adjusted EBITDA margin improved to 23.2% in Q3 2025 (from 22.9%) and 22.2% for the nine months (from 21.2%), indicating enhanced profitability.
• Strategic acquisition of an additional 31% equity interest in BTY strengthens the Aptar Beauty segment's position in the Chinese market for decorative metal components and packaging solutions.
• The company maintains a strong financial position with a Consolidated Leverage Ratio of 1.22 to 1.00 (well below the maximum of 3.50 to 1.00) and a Consolidated Interest Coverage Ratio of 17.02 to 1.00 (well above the minimum of 3.00 to 1.00).
• Cash and equivalents increased to $257.1 million at September 30, 2025, from $223.8 million at December 31, 2024.
• Restructuring costs decreased year-over-year, indicating progress in cost reduction measures.

Negatives

• Operating income decreased by 1% to $136.9 million in Q3 2025, primarily due to higher cost of sales, depreciation, amortization, and legal expenses, despite cost management efforts.
• Cost of sales as a percentage of net sales increased to 62.2% in Q3 2025 (from 61.4%), impacted by a mix of lower-margin applications in the Pharma segment and lower productivity.
• Aptar Beauty segment's Adjusted EBITDA decreased 1% in Q3 2025 and 2% for the nine months, with its margin declining to 12.1% (from 13.3%) in Q3 and 12.8% (from 13.2%) for the nine months, attributed to increased input costs and lower product/tooling margins.
• Aptar Closures segment's Adjusted EBITDA decreased 5% in Q3 2025, with its margin declining to 16.1% (from 17.2%), mainly due to lower tooling sales and lower productivity.
• Core sales in the Consumer Health Care market within Aptar Pharma declined significantly by 11% in both Q3 and YTD due to softer nasal decongestant, nasal saline, and cough/cold product volumes.
• Core sales in the Beauty market within Aptar Beauty decreased 5% in Q3 and 7% YTD due to softer demand for prestige fragrance technologies and facial skin care products.
• Core sales in the Home Care market within Aptar Beauty decreased 18% in Q3 and 1% YTD due to lower demand from air care and automotive customers.
• Interest expense increased by $1.2 million in Q3 2025 and $3.2 million for the nine months due to higher rates on current year borrowings, reflecting rising interest rate environment.
• The company is involved in several legal proceedings, including an antitrust lawsuit filed against it by ARS Pharmaceuticals, Inc., and patent infringement actions by Nemera, which could result in substantial costs and diversion of management attention.

Risks

• Geopolitical conflicts worldwide and their indirect impact on customer demand and supply chain disruptions.
• Ability to protect and defend intellectual property rights, and potential litigation involving IP infringement.
• Cybersecurity threats against systems and service providers.
• Availability of raw materials and components, particularly from sole-sourced suppliers for Pharma solutions, and the financial viability of these suppliers.
• Outcome of any legal proceedings, which could result in substantial costs, operational disruptions, or restrictions on manufacturing/sales.
• Lower demand and asset utilization due to a global or key market economic recession.
• Economic conditions worldwide, including inflationary and potential deflationary conditions.
• Competition, including technological advances.
• Significant tariffs and other restrictions on foreign imports and related countermeasures.
• Fluctuations in the cost of materials, components, transportation, and labor.
• Significant fluctuations in foreign currency exchange rates or the effective tax rate.
• Impact of tax reform legislation, changes in tax rates, and other tax-related events.
• Financial conditions of customers and suppliers.
• Consolidations within customer or supplier bases.
• Changes in customer and/or consumer spending levels.
• Loss of one or more key accounts.
• Ability to offset inflationary impacts with cost containment, productivity initiatives, and price increases.
• Changes in capital availability or cost, including rising interest rates.
• Loss of royalty revenue due to contract expirations.
• Volatility of global credit markets.
• Ability to identify, successfully acquire, and integrate new businesses.
• Ability to build out acquired businesses and integrate product/service offerings.
• Direct or indirect consequences of acts of war, terrorism, or social unrest.
• Impact of natural disasters and other weather-related occurrences.
• Fiscal and monetary policies and other regulations.
• Changes, difficulties, or failures in complying with government regulation, including FDA or similar foreign governmental authorities.
• Changing regulations or market conditions regarding environmental sustainability.
• Ability to retain key members of management and manage labor costs.
• Work stoppages due to labor disputes.
• Ability to meet future cash flow estimates to support goodwill impairment testing.
• Success of customers' products, particularly in the pharmaceutical industry.
• Ability to manage worldwide customer launches of complex technical products, especially in developing markets.
• Difficulties in product development and uncertainties related to timing or outcome of product development.
• Significant product liability claims.

Future Outlook

AptarGroup expects adjusted earnings per share for the fourth quarter of 2025 to be in the range of $1.20 to $1.28, based on an estimated effective tax rate range of 19.5% to 21.5%. Total estimated cash outlays for capital expenditures, net of government grant proceeds, for 2025 are projected to be approximately $250 million to $270 million.

Management Comments

• Strong product volume growth in our Aptar Pharma and Aptar Closures segments more than compensated for lower tooling sales and the pass through of lower resin costs.
• Cost management efforts were more than offset by higher cost of sales, depreciation, amortization and legal expenses.
• The increase in year-to-date operating income was driven by sales growth from our Aptar Pharma segment and effective cost management efforts which more than compensated for higher legal expenses.

Industry Context

The filing indicates a mixed industry environment. The Pharma segment continues to show strong demand, particularly in prescription drug and injectables, aligning with broader healthcare growth trends. However, the Beauty segment faces softness in prestige fragrance and facial skincare, while the Home Care market also sees lower demand, suggesting some consumer discretionary spending pressures or shifts. The Closures segment experiences varied performance, with beverage sales improving but tooling sales and resin cost pass-throughs impacting overall results. The company's strategic acquisitions in beauty packaging (BTY) and pharma dosing (Sommaplast) reflect efforts to strengthen positions in key growth areas and diversify its portfolio.

Corporate Governance

Legal Proceedings

• AptarGroup, Inc. and Aptar France SAS filed a lawsuit on March 25, 2025, in the U.S. District Court for the Southern District of New York against ARS Pharmaceuticals, Inc., alleging misappropriation of trade secrets and breach of contractual confidentiality obligations. Aptar seeks injunctive relief and damages.
• ARS Pharmaceuticals, Inc. filed a lawsuit on September 29, 2025, in the U.S. District Court for the Southern District of California against Aptar, alleging violations of Sections 1 and 2 of the Sherman Act and Section 3 of the Clayton Act by refusing to sell certain components. ARS seeks injunctive relief and damages.
• In May 2025, Nemera La Verpillire SAS filed parallel patent infringement actions in Mannheim Regional Court, Germany, and Paris Judicial Court, France, against Aptar and certain subsidiaries. Nemera alleges that Aptar's ophthalmic product infringes a Nemera patent and seeks an injunction and damages. Aptar is contesting the claims and filed oppositions before the European Patent Office (EPO). On October 2, 2025, an EPO hearing invalidated Nemera's main patent claim while allowing an amended claim to continue. The infringement proceedings in Germany and France are ongoing.
• The company is subject to loss contingencies from customs duties assessments, with claims worth approximately $10 million to $11 million in principal, and $22 million to $23 million for interest and penalties. No liability is recorded as of September 30, 2025, due to uncertainty in settlement probability and appeal timing.

Related Party Transactions

• For the year-to-date period through July 28, 2025, prior to consolidation, Aptar had purchases of $7.4 million from BTY. For the nine months ended September 30, 2024, Aptar had purchases of $8.7 million from BTY.
• As of July 28, 2025, and December 31, 2024, approximately $2.1 million and $2.5 million, respectively, was due to BTY and included in accounts payable, accrued and other liabilities.

Stakeholder Impact

• Shareholders: Positive impact from increased net income and EPS, ongoing share repurchase program, and consistent dividend payments. Potential for future growth from strategic acquisitions. However, legal proceedings and some segment softness could introduce volatility.
• Employees: Restructuring initiatives are ongoing, which may involve severance costs, but the company continues to invest in growth strategies. Stock-based compensation plans are in place.
• Customers: Strong demand for Pharma products, but some softness in beauty and home care markets. Acquisitions like Sommaplast and BTY aim to enhance product offerings and market reach.
• Suppliers: The company utilizes a supply chain finance program to extend payment terms, which could impact supplier cash flow if they opt for early payment through the third-party platform. Risks related to raw material availability and supplier financial viability are noted.
• Creditors: The company maintains strong financial covenants (leverage and interest coverage ratios) and has extended its revolving credit facility, indicating good creditworthiness.

Next Steps

• Complete the acquisition of Sommaplast, anticipated in the fourth quarter of 2025, subject to regulatory approvals and customary closing conditions.
• Continue to evaluate the impact of ASU 2023-09 (Improvements to Income Tax Disclosures) and adopt this guidance in the fourth quarter of 2025.
• Continue to evaluate the impact of ASU 2024-03 (Disaggregation of Income Statement Expenses) on disclosures.
• Manage ongoing legal proceedings, including the lawsuit against ARS Pharmaceuticals and patent infringement actions by Nemera.
• Continue share repurchases under the existing $500 million authorization, with $272.7 million remaining.
• Pay a quarterly cash dividend of $0.48 per share on November 13, 2025.

Key Dates

Recommendation

AptarGroup's Q3 2025 results show a significant increase in net income and EPS, primarily driven by a one-time gain from an equity investment remeasurement and a favorable tax rate. While the Pharma segment continues to perform strongly and strategic acquisitions are positive for long-term growth, core sales growth remains modest, and operating income saw a slight decline in the quarter due to increased costs and some segment-specific softness in Beauty and Closures. The company's strong balance sheet and ongoing share repurchase program are supportive. However, the reliance on a one-time gain for the headline earnings boost, coupled with ongoing legal challenges and mixed segment performance, suggests a 'hold' recommendation. Investors should monitor core operational improvements and the integration of recent acquisitions for sustained organic growth.

Keywords

AptarGroup, ATR, SEC Filing, 10-Q, Quarterly Report, Financial Results, Earnings, Pharma, Beauty, Closures, Packaging, Dispensing Systems, Drug Delivery, Acquisitions, BTY, Sommaplast, Share Repurchase, EPS, EBITDA, Core Sales, Corporate Governance, Legal Proceedings, Risk Management